Finance

Lists
Why is 600812 down 4,72%?
Dive Deeper
600812:SHA
North China Pharmaceutical Co Ltd
6,26 CN¥
-4,72%
(-0,31) 1D
16-окт., 15:00:00 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600812...
Open
6,33 CN¥
High
6,90 CN¥
Low
6,10 CN¥
Avg. vol.
61,12 млн
Volume
307,76 млн
Dividend
0,56%
Quarterly dividend
0,01 CN¥
Ex-dividend date
2026-ж., 11-июн.
P/E ratio
87,26
52-wk high
6,90 CN¥
52-wk low
4,11 CN¥
EPS
0,07 CN¥
Shares outstanding
1,63 млд
No. of employees
10 миң
Open
6,33 CN¥
High
6,90 CN¥
Low
6,10 CN¥
Avg. vol.
61,12 млн
Volume
307,76 млн
Dividend
0,56%
Quarterly dividend
0,01 CN¥
Ex-dividend date
2026-ж., 11-июн.
P/E ratio
87,26
52-wk high
6,90 CN¥
52-wk low
4,11 CN¥
EPS
0,07 CN¥
Shares outstanding
1,63 млд
No. of employees
10 миң
News stories
From web sources and news partners
Profile
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
About North China Pharmaceutical Co Ltd
CEO-
Employees9,97 миң
Founded1992-ж., 20-дек.
Headquarters-
SectorPharmaceutical industry
Website-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
2,21 млд
1,76 млд
2,15 млд
2,07 млд
Cost of goods sold
1,59 млд
1,07 млд
1,53 млд
1,54 млд
Cost of revenue
1,59 млд
1,07 млд
1,53 млд
1,54 млд
Research and development expenses
85,19 млн
85,95 млн
95,62 млн
84,71 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
419,54 млн
414,91 млн
354,22 млн
304,68 млн
Operating expense
504,74 млн
539,54 млн
495,25 млн
396,76 млн
Total operating expenses
2,09 млд
1,61 млд
2,03 млд
1,94 млд
Operating income
116,01 млн
149,57 млн
128,11 млн
125,58 млн
Other non operating income
-299,86 миң
-2,96 млн
-10,58 млн
6,02 млн
EBT including unusual items
73,18 млн
70,19 млн
66,28 млн
57,65 млн
EBT excluding unusual items
45,54 млн
84,31 млн
61,80 млн
58,08 млн
Income tax expense
23,93 млн
24,28 млн
16,90 млн
16,15 млн
Effective tax rate
32,70%
34,59%
25,50%
28,02%
Other operating expenses
4,82 млн
29,30 млн
27,82 млн
15,57 млн
Net income
35,01 млн
24,55 млн
35,47 млн
28,37 млн
Net profit margin
1,58%
1,40%
1,65%
1,37%
Earnings per share
-
-
-
-
Interest and investment income
19,41 млн
27,71 млн
19,26 млн
22,40 млн
Interest expense
-85,85 млн
-85,06 млн
-74,99 млн
-76,52 млн
Net interest expenses
-66,43 млн
-57,35 млн
-55,73 млн
-54,13 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
313,14 млн
371,92 млн
350,45 млн
367,38 млн
Gain or loss from assets sale
-9,85 миң
-827,34 миң
-
-217,80 миң
AI content may include mistakes. Learn more
Google колдонмолору